3 results about "Double antibody" patented technology

The application provides a kind of bispecific antibody and its preparation and application, the bispecific antibody includes two chains: from N end to C end in order: VH1 (or VL1), L1, VH2, CH1, the first polypeptide chain of Fc, and from N end to C end in order: VL1 (or VH1), L2, VL2, CL, second polypeptide chain.It is realized tumor selective accumulation by being located in the N end of double antibody structure of the binding domain targeted to tumor associated antigen (TAA), and its shield is located in the inside immune checkpoint antibody fragment to the binding activity of immune checkpoint to reduce systemic activity.

The invention provides dual-specific antibodies and methods for manufacturing and using these antibodies. In general, the dual-specific antibodies are generated by identifying a monospecific antibody with electrostatic or hydrophobic light chain variable region (VL) residues and altering the nucleic acid sequence encoding one or more solvent-accessible residues in the antibody's VH, either alone or in combination with altering the nucleic acid sequence encoding the antibody's VL. The altered VH and VL are expressed, and dual-specific antibodies or antigen-binding fragments are selected from them. Examples of dual-specific antibodies and methods for using the antibodies are also provided.

The application discloses a special elution buffer system for significantly removing half-antibody fragment impurities in double-antibody culture and belongs to the technical field of biology. In the elution stage of the eluent in the affinity chromatography capture, the application adds ammonium sulfate to the eluent, removes the half-antibody fragment, improves the purity of the target protein after the affinity chromatography, and makes the purity of the double-antibody meet the demand of a medicine (the SEC-HPLC purity is greater than 97%) after the purification. By using the elution system method, the purity of the half-antibody fragment nr-CE is reduced from 6% to 0.2%.